Literature DB >> 22246947

Atrial fibrillation and vascular disease--a bad combination.

Jonas Bjerring Olesen1, Gunnar Hilmar Gislason, Christian Torp-Pedersen, Gregory Y H Lip.   

Abstract

This article provides an overview of (i) the risk of stroke associated with vascular disease (acute coronary syndromes and peripheral artery disease) in patients with atrial fibrillation, (ii) the frequent coexistence of vascular disease in patients with atrial fibrillation and, (iii) the cardiovascular risk associated with the coexisting of the two diseases. The literature on this topic is relatively sparse, and we discuss results from both clinical trials and observational studies. There is a clear indication of an increased stroke risk associated with vascular disease in patients with atrial fibrillation. Indeed, patients with atrial fibrillation often had coexisting vascular disease (around 18%), and the combination of the two diseases substantially increases the risk of future cardiovascular events. The increased risk associated with peripheral artery disease in atrial fibrillation is even more pronounced. Patients with atrial fibrillation and stable vascular disease should be treated with oral anticoagulation only, although when these patients present with acute coronary syndrome and/or undergo coronary stenting, concomitant treatment with antiplatelet drugs is indicated. To guide antithrombotic management in patients with atrial fibrillation, several stroke and bleeding risk prediction schemes have been developed.
© 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22246947      PMCID: PMC6652656          DOI: 10.1002/clc.20955

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  6 in total

1.  CHADS2 and CHA2DS2-VASc scores are independently associated with incident atrial fibrillation: the Catanzaro Atrial Fibrillation Project.

Authors:  Angela Sciacqua; Maria Perticone; Giovanni Tripepi; Eliezer J Tassone; Antonio Cimellaro; Deborah Mazzaferro; Giorgio Sesti; Francesco Perticone
Journal:  Intern Emerg Med       Date:  2015-05-05       Impact factor: 3.397

Review 2.  Atherosclerosis and Atrial Fibrillation: Double Trouble.

Authors:  Mehran Abolbashari
Journal:  Curr Cardiol Rep       Date:  2022-01-06       Impact factor: 2.931

Review 3.  Atrial fibrillation and risk of cardiovascular events and mortality in patients with symptomatic peripheral artery disease: A meta-analysis of prospective studies.

Authors:  Mislav Vrsalović; Ana Vrsalović Presečki
Journal:  Clin Cardiol       Date:  2017-12-15       Impact factor: 2.882

Review 4.  The case for dosing dabigatran: how tailoring dose to patient renal function, weight and age could improve the benefit-risk ratio.

Authors:  Apostolos Safouris; Nikos Triantafyllou; John Parissis; Georgios Tsivgoulis
Journal:  Ther Adv Neurol Disord       Date:  2015-11       Impact factor: 6.570

5.  Functional Outcome and Safety of Intracranial Thrombectomy After Emergent Extracranial Stenting in Acute Ischemic Stroke Due to Tandem Occlusions.

Authors:  Philipp Bücke; Marta Aguilar Pérez; Muhammad AlMatter; Victoria Hellstern; Hansjörg Bäzner; Hans Henkes
Journal:  Front Neurol       Date:  2018-11-20       Impact factor: 4.003

6.  Risk of death in heart disease is associated with elevated urinary globotriaosylceramide.

Authors:  Raphael Schiffmann; Sabrina Forni; Caren Swift; Nastry Brignol; Xiaoyang Wu; David J Lockhart; Derek Blankenship; Xuan Wang; Paul A Grayburn; Matthew R G Taylor; Brian D Lowes; Maria Fuller; Elfrida R Benjamin; Lawrence Sweetman
Journal:  J Am Heart Assoc       Date:  2014-02-04       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.